ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock Earnings Estimates
NASDAQ:ARWR • US04280A1007
63.82 USD
+1.44 (+2.31%)
At close: Feb 13, 2026
63.82 USD
0 (0%)
After Hours: 2/13/2026, 8:00:00 PM
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 240.7M -1.03% | 3.551M -98.52% | 829.448M 23,258.15% | 410.29M -50.53% | 281.6M -31.37% | 506.97M 80.03% | 884.75M 74.52% | 1.539B 73.95% | 2.094B 36.06% | 3.19B 52.34% | 4.036B 26.52% | |
| EBITDA YoY % growth | -192.5M -14.52% | -582.485M -202.59% | 122.274M 120.99% | -284.77M -332.89% | -669.776M -135.20% | -633.199M 5.46% | -154.02M 75.68% | 540.6M 450.99% | 1.065B 97.00% | N/A | N/A | |
| EBIT YoY % growth | -205M -14.85% | -601.08M -193.21% | 98.346M 116.36% | -411.932M -518.86% | -624.106M -51.51% | -471.078M 24.52% | -247.84M 47.39% | 353.06M 242.46% | 777.53M 120.23% | 1.412B 81.60% | 2.044B 44.76% | |
| Operating Margin | -85.17% | -16,927.06% | 11.86% | -100.40% | -221.63% | -92.92% | -28.01% | 22.94% | 37.13% | 44.26% | 50.64% | |
| EPS YoY % growth | -1.92 -14.29% | -5.01 -160.94% | -0.08 98.40% | -3.44 -4,201.00% | -4.64 -34.83% | -3.43 26.02% | -2.33 32.24% | 2.42 204.24% | 5.37 121.32% | 10.13 88.88% | 15.21 50.08% |
All data in USD
| Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.18 -142.99% | -1.33 -5.48% | -1.37 -659.33% | -1.19 -642.45% | -1.32 -11.29% | -1.34 -0.54% | -0.87 36.19% |
| Revenue Q2Q % growth | 76.028M -86.00% | 41.623M 49.90% | 44.877M -82.50% | 57.579M -78.19% | 40.545M -46.67% | 43.146M 3.66% | 135.41M 201.74% |
| EBITDA Q2Q % growth | -167.077M -142.57% | -187.078M -26.40% | -201.79M -396.60% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -173.501M -145.51% | -175.521M -6.02% | -188.466M -527.30% | -168.888M -513.85% | -171.135M 1.36% | -167.451M 4.60% | -170.018M 9.79% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2026 Q2Q % growth | 0.22 115.83% | 0.26 | -0.04 | -14.75% |
| Q4 2025 Q2Q % growth | -0.18 86.86% | -0.25 | 0.07 | 26.70% |
| Q3 2025 Q2Q % growth | -1.26 8.70% | -1.05 | -0.21 | -20.51% |
| Q2 2025 Q2Q % growth | 2.75 369.61% | -0.20 | 2.95 | 1,461.66% |
| Q1 2025 Q2Q % growth | -1.39 -12.10% | -0.45 | -0.94 | -211.36% |
| Q4 2024 Q2Q % growth | -1.37 -34.31% | -1.07 | -0.30 | -28.19% |
| Q3 2024 Q2Q % growth | -1.38 -43.75% | -0.56 | -0.82 | -145.24% |
| Q2 2024 Q2Q % growth | -1.02 -326.67% | -0.17 | -0.85 | -515.69% |
| Q1 2024 Q2Q % growth | -1.24 -217.95% | -0.84 | -0.40 | -48.25% |
| Q4 2023 Q2Q % growth | -1.02 -25.93% | -0.62 | -0.40 | -65.77% |
| Q3 2023 Q2Q % growth | -0.96 -41.18% | -0.67 | -0.29 | -44.13% |
| Q2 2023 Q2Q % growth | 0.45 9.76% | -0.65 | 1.10 | 168.84% |
| Q1 2023 Q2Q % growth | -0.39 35.00% | 0.45 | -0.84 | -187.62% |
| Q4 2022 Q2Q % growth | -0.81 -32.79% | -0.17 | -0.64 | -379.95% |
| Q3 2022 Q2Q % growth | -0.68 -134.48% | -0.52 | -0.16 | -31.80% |
| Q2 2022 Q2Q % growth | 0.41 257.69% | -0.08 | 0.49 | 596.25% |
| Q1 2022 Q2Q % growth | -0.60 -200.00% | -0.46 | -0.14 | -31.60% |
| Q4 2021 Q2Q % growth | -0.61 -27.08% | -0.11 | -0.50 | -467.08% |
| Q3 2021 Q2Q % growth | -0.29 -123.08% | -0.20 | -0.09 | -44.10% |
| Q2 2021 Q2Q % growth | -0.26 -30.00% | -0.13 | -0.13 | -94.14% |
| Q1 2021 Q2Q % growth | -0.20 -566.67% | 0.12 | -0.32 | -266.32% |
| Q4 2020 Q2Q % growth | -0.48 | 0.12 | -0.60 | -504.42% |
| Q3 2020 Q2Q % growth | -0.13 | -0.12 | -0.01 | -9.87% |
| Q2 2020 Q2Q % growth | -0.20 | -0.11 | -0.09 | -80.07% |
| Q1 2020 Q2Q % growth | -0.03 | -0.01 | -0.02 | -311.93% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2026 Q2Q % growth | 264.033M 10,461.32% | 275.47M | -11.437M | -4.15% |
| Q4 2025 Q2Q % growth | 256.472M | 179.38M | 77.092M | 42.98% |
| Q3 2025 Q2Q % growth | 27.767M | 24.185M | 3.582M | 14.81% |
| Q2 2025 Q2Q % growth | 543M | 30.504M | 512.496M | 1,680.09% |
| Q1 2025 Q2Q % growth | 2.5M -29.60% | 74.205M | -71.705M | -96.63% |
| Q4 2024 Q2Q % growth | -100.00% | 65.099M | -65.099M | -100.00% |
| Q3 2024 Q2Q % growth | -100.00% | 53.688M | -53.688M | -100.00% |
| Q2 2024 Q2Q % growth | -100.00% | 65.147M | -65.147M | -100.00% |
| Q1 2024 Q2Q % growth | 3.551M -94.32% | 30.101M | -26.55M | -88.20% |
| Q4 2023 Q2Q % growth | 16.097M -49.06% | 51.743M | -35.646M | -68.89% |
| Q3 2023 Q2Q % growth | 15.825M -51.16% | 50.169M | -34.344M | -68.46% |
| Q2 2023 Q2Q % growth | 146.267M -3.64% | 46.389M | 99.878M | 215.31% |
| Q1 2023 Q2Q % growth | 62.5M 128.10% | 165.77M | -103.27M | -62.30% |
| Q4 2022 Q2Q % growth | 31.6M -17.49% | 51.453M | -19.853M | -38.58% |
| Q3 2022 Q2Q % growth | 32.4M -29.41% | 56.332M | -23.932M | -42.48% |
| Q2 2022 Q2Q % growth | 151.8M 362.80% | 111.09M | 40.71M | 36.65% |
| Q1 2022 Q2Q % growth | 27.4M 28.64% | 52.065M | -24.665M | -47.37% |
| Q4 2021 Q2Q % growth | 38.3M 403.95% | 57.91M | -19.61M | -33.86% |
| Q3 2021 Q2Q % growth | 45.9M 67.52% | 38.267M | 7.633M | 19.95% |
| Q2 2021 Q2Q % growth | 32.8M 39.57% | 38.451M | -5.651M | -14.70% |
| Q1 2021 Q2Q % growth | 21.3M -27.80% | 77.076M | -55.776M | -72.36% |
| Q4 2020 Q2Q % growth | 7.6M | 50.227M | -42.627M | -84.87% |
| Q3 2020 Q2Q % growth | 27.4M | 29.49M | -2.09M | -7.09% |
| Q2 2020 Q2Q % growth | 23.5M | 22.175M | 1.325M | 5.98% |
| Q1 2020 Q2Q % growth | 29.5M | 30.09M | -590K | -1.96% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -4.05% | -29.08% | -4.44% | -25.24% |
| Revenue | 8.46% | -3.48% | 0.19% | -2.7% |